- Home
- ELVA vs AGEN Comparison
ELVA vs AGEN Comparison
Compare ELVA & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELVA
- AGEN
- Stock Information
- Founded
- ELVA 1996
- AGEN 1994
- Country
- ELVA Canada
- AGEN United States
- Employees
- ELVA N/A
- AGEN N/A
- Industry
- ELVA
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ELVA
- AGEN Health Care
- Exchange
- ELVA Nasdaq
- AGEN Nasdaq
- Market Cap
- ELVA 125.5M
- AGEN 123.6M
- IPO Year
- ELVA N/A
- AGEN 2000
- Fundamental
- Price
- ELVA $6.41
- AGEN $3.85
- Analyst Decision
- ELVA Strong Buy
- AGEN Buy
- Analyst Count
- ELVA 3
- AGEN 2
- Target Price
- ELVA $6.50
- AGEN $14.50
- AVG Volume (30 Days)
- ELVA 522.0K
- AGEN 470.9K
- Earning Date
- ELVA 12-11-2025
- AGEN 11-11-2025
- Dividend Yield
- ELVA N/A
- AGEN N/A
- EPS Growth
- ELVA 58.59
- AGEN N/A
- EPS
- ELVA 0.03
- AGEN N/A
- Revenue
- ELVA $54,875,000.00
- AGEN $101,706,000.00
- Revenue This Year
- ELVA $46.40
- AGEN $60.49
- Revenue Next Year
- ELVA $46.08
- AGEN N/A
- P/E Ratio
- ELVA $238.81
- AGEN N/A
- Revenue Growth
- ELVA 10.88
- AGEN N/A
- 52 Week Low
- ELVA $1.73
- AGEN $1.38
- 52 Week High
- ELVA $7.72
- AGEN $7.34
- Technical
- Relative Strength Index (RSI)
- ELVA 51.12
- AGEN 40.32
- Support Level
- ELVA $6.11
- AGEN $3.96
- Resistance Level
- ELVA $6.62
- AGEN $4.60
- Average True Range (ATR)
- ELVA 0.49
- AGEN 0.25
- MACD
- ELVA -0.06
- AGEN 0.01
- Stochastic Oscillator
- ELVA 36.33
- AGEN 2.60
About ELVA Electrovaya Inc.
Electrovaya Inc designs develop and manufacture proprietary lithium-ion batteries, battery systems, and battery-related products for energy storage, clean electric transportation and other specialized applications. It is a technology-focused company with extensive IP. The company generates revenue from the sale of batteries and battery systems. Business operations are segmented based on large format batteries and others. This technology offers enhanced safety and battery longevity. Geographically it earns key revenue from the United States.
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).